Cell & Gene Interview Apr 27 2017

Hi all

Thought this 14 minute interview on 27 April 2017 may be a good outline of how MSCs work and summary of the recent progress made with our phase 3 programs.



brief notes:
-Potential CHF breakthrough or RAT designation after NIH read out end of this year
-Talks about Japan aGVHD & Phase 3 trial in US, read out end of 2017/early 2018
-Disc program; single administration shows durable effects
-MNK hospital based w $3bn in revenue, committed to regenerative medicine. MNK need to diversify their revenue, so far interaction is positive.
-RA; Interviewer believes this is game-changing data.
- Financing: Non-dilutive funding mentioned.